Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Treasury Shares (2016 - 2025)

United Therapeutics' Treasury Shares history spans 17 years, with the latest figure at $4.3 billion for Q4 2025.

  • For Q4 2025, Treasury Shares rose 22.62% year-over-year to $4.3 billion; the TTM value through Dec 2025 reached $4.3 billion, up 22.62%, while the annual FY2025 figure was $4.3 billion, 22.62% up from the prior year.
  • Treasury Shares for Q4 2025 was $32.8 million at United Therapeutics, roughly flat from $32.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $32.8 million in Q4 2025 and bottomed at $26.6 million in Q1 2021.
  • The 5-year median for Treasury Shares is $26.6 million (2021), against an average of $28.3 million.
  • The largest annual shift saw Treasury Shares changed 0.0% in 2021 before it skyrocketed 34.74% in 2024.
  • A 5-year view of Treasury Shares shows it stood at $2.6 billion in 2021, then changed by 0.0% to $2.6 billion in 2022, then changed by 0.0% to $2.6 billion in 2023, then soared by 34.71% to $3.5 billion in 2024, then rose by 22.62% to $4.3 billion in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Treasury Shares are $4.3 billion (Q4 2025), $4.3 billion (Q3 2025), and $3.5 billion (Q2 2025).